Lakefront Biotherapeutics American Depositary Shares
LKFT
74 hedge funds and large institutions have $585M invested in Lakefront Biotherapeutics American Depositary Shares in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 19 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
6% more capital invested
Capital invested by funds: $551M → $585M (+$33.8M)
0.39% more ownership
Funds ownership: 19.63% → 20.02% (+0.39%)
7% less call options, than puts
Call options by funds: $17.2M | Put options by funds: $18.6M
11% less funds holding
Funds holding: 83 → 74 (-9)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$22.4M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$8.2M |
| 3 |
Millennium Management
New York
|
+$8.17M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.44M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$4.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$13.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.1M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$5.25M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.63M |
| 5 |
Optiver Holding
Amsterdam,
Netherlands
|
-$2.84M |
LKFT Hedge Fund Activity: Q4 2022 in Review
74 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2022, worth a combined $585M — up 6.1% from $551M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LKFT and 12 opened new positions — a net loss of 7 holders — while 24 trimmed existing stakes and 29 added.
The largest buyer was EcoR1 Capital, adding an estimated $22.4M. The largest seller was Driehaus Capital Management, cutting an estimated $13.4M.
- 74 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2022, down from 83 in Q3 2022.
- Funds reported $585M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2022, up 6.1% quarter-over-quarter.
- 12 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2022 and 19 closed out, a net change of -7 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2022 was EcoR1 Capital, an estimated $22.4M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2022 was Driehaus Capital Management, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2022.